ALS treatment
adapted for
the real world

Teglutik® – a patented formulation that represents a significant advance using riluzole in ALS1,2

By its nature, riluzole is insoluble in water and causes a strong and persistent anaesthetic effect in the mouth (lasting >20–30 minutes)1 – this is not ideal for administrating as a crushed tablet and is possibly one of the leading causes of unintentional non-adherence* to treatment in ALS.

By enclosing riluzole in a unique liquid-suspension formulation, Teglutik®:1

Teglutik® – a patented formulation that represents a significant advance using riluzole in ALS
*Unintentional non-adherence is defined in NICE guidance CG76 as “when the patient wants to follow the agreed treatment but is prevented from doing so by barriers that are beyond their control. Examples include…problems with using the treatment”.3

The development of Teglutik® as an oral suspension represents novelty and innovation, recognised by the international patent granted for its formulation.2

Welcome
to Teglutik®

Teglutik® is the first oral liquid suspension formulation of riluzole, the only licensed treatment for patients with amyotrophic lateral sclerosis (ALS), the most common type of motor neuron disease (MND).

This site provides information on Teglutik® and ALS for UK-based healthcare professionals and patients. Please select from the buttons below to tailor the content to your needs:

I am a UK healthcare professional
I am not a healthcare professional

For additional information about MND you can visit the Motor Neurone Disease Association website. The Motor Neurone Disease Association is the only national charity in England, Wales and Northern Ireland focused on MND care, research and campaigning

http://www.mndassociation.org/